Other OTC - Delayed Quote USD

Endonovo Therapeutics, Inc. (ENDV)

0.0026 -0.0002 (-7.42%)
At close: April 19 at 2:52 PM EDT
Loading Chart for ENDV
DELL
  • Previous Close 0.0028
  • Open 0.0027
  • Bid --
  • Ask --
  • Day's Range 0.0026 - 0.0027
  • 52 Week Range 0.0010 - 0.0200
  • Volume 45,366
  • Avg. Volume 1,242,931
  • Market Cap (intraday) 835,130
  • Beta (5Y Monthly) -0.36
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0700
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

www.endonovo.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ENDV

Performance Overview: ENDV

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ENDV
69.89%
S&P 500
4.14%

1-Year Return

ENDV
81.93%
S&P 500
19.55%

3-Year Return

ENDV
91.38%
S&P 500
18.68%

5-Year Return

ENDV
99.98%
S&P 500
70.99%

Compare To: ENDV

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ENDV

Valuation Measures

As of 4/19/2024
  • Market Cap

    835.13k

  • Enterprise Value

    7.89M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.86

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    30.86

  • Enterprise Value/EBITDA

    -3.11

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -144.27%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    255.72k

  • Net Income Avi to Common (ttm)

    -4.4M

  • Diluted EPS (ttm)

    -0.0700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    2.15M

People Also Watch